Our pellets are now being produced by Belmar Select Outsourcing (BSO). The great news is that the same quality and high standards used at Belmar Pharmacy, now meet cGMP and FDA requirements. BSO is a cGMP and FDA registered 503B Outsourcing Facility for hormone pellet implants. BSO is licensed in 35 states and we have a two-day turnaround shipping out your pellet orders.
Belmar Select Outsourcing's mission is to provide quality hormone pellet implants to clinicians at a reasonable price.  We use state of the art methodology to compound manufacture our hormone pellet implants in estradiol, testosterone, testosterone with cholesterol, progesterone, and anastrozole.  Our pellets are sterilized using the most advanced sterilization technique uniquely suited for this dosage form.  Every batch is tested for potency and endotoxins.  We have also implemented a risk-based environmental monitoring program.Because we are a 503B Outsourcing Facility, we do not require patient specific prescriptions and can ship the pellets to your office in bulk.  We do not require contracts when working with us.  
Call or visit our website for available pellet strengths: 
T: (877) 267-3410 | (303) 963-5488 


Pharmacokinetics and Pharmacodynamics
Blanchemain N, Siepmann F, Siepmann J. Implants for drug substance delivery. Med Sci (Paris), 2017; 33(1):32-38. 
McFarland J, Craig W, Clarke NJ, Spratt DI.  Serum Testosterone Concentrations Remain Stable Between Injections in Patients Receiving Subcutaneous TestosteroneJ Endocr Soc, 2017;1(8):1095-1103.   
Glaser R, Kalantaridou S, Dimitrakakis C.  Testosterone implants in women: pharmacological dosing for physiologic effect. Maturitas, 2013; 74(2):179-84. 
Pastuszak A, Mittakanti H, Liu J, et al. Pharmacokinetic Evaluation and Dosing of Subcutaneous Testosterone Pellets. Journal of Andrology, 2012; 33(5):927-937.
Kelleher S, Howe C, Conway AJ, Handelsman DJ.  Testosterone release rate and duration of action of testosterone pellet implantsClin Endocrinol (Oxf), 2004; 60(4):420-8.

Cravioto M, Larrea F, Delgado N, et al. Pharmacokinetics and pharmacodynamics of 25-mg estradiol implants in postmenopausal Mexican women. Menopause, 2001; 8(5):353-360.

Patient Adherence and Satisfaction
Piecuch MJ, Patel BG, Hakim L, Wang R, Sadeghi-Nejad H.  Testosterone Pellet Implantation Practices: A Sexual Medicine Society of North America (SMSNA) Member QuestionnaireJ Sex Med, 2017; 14(1):47-49.
Spratt DI, Stewart II, Savage C, Craig W, Spack NP, Chandler DW, Spratt LV, Eimicke T, Olshan JS.  Subcutaneous Injection of Testosterone Is an Effective and Preferred Alternative to Intramuscular Injection: Demonstration in Female-to-Male Transgender PatientsJ Clin Endocrinol Metab, 2017; 102(7):2349-2355. 
Pastuszak AW, Gomez LP, Scovell JM, Khera M, Lamb DJ, Lipshultz LI.  Comparison of the Effects of Testosterone Gels, Injections, and Pellets on Serum Hormones, Erythrocytosis, Lipids, and Prostate-Specific Antigen.  Sex Med, 2015; 3(3):165-73.
Kovac JR, Rajanahally S, Smith RP, Coward RM, Lamb DJ, Lipshultz LI. Patient satisfaction with testosterone replacement therapies: the reasons behind the choicesJ Sex Med, 2014; 11(2):553-62.   
McCullough A. A Review of Testosterone Pellets in the Treatment of HypogonadismCurr Sex Health Rep, 2014;6(4):265-269. 
Smith RP, Khanna A, Coward RM, Rajanahally S, Kovac JR, Gonzales MA, Lipshultz LI.  Factors influencing patient decisions to initiate and discontinue subcutaneous testosteronepellets 
(Testopel) for treatment of hypogonadismJ Sex Med, 2013;10(9):2326-33.
Britto R, Ara├║jo L, Barbosa I, Silva L.  Improvement of the lipid profile in post menopausal women who use estradiol and testosterone implants. Gynecological Endocrinology, 2012; 28(10):767-769. 

Studd J, Savvas M, Waston N, et al. The relationship between plasma estradiol and the increase in bone density in postmenopausal women after treatment with subcutaneous hormone implants. American Journal of Obstetrics and Gynecology, 1990; 163(5):1474-1479.
Stanczyk F, Shoupe D, Nunez V, et al. A randomized comparison of nonoral estradiol delivery in postmenopausal women.  American Journal of Obstetrics and Gynecology, 1988; 159(6):1540-1546. 
Greenblatt R, Bryner J, Mahesh V, Asch R. Implantation of pure crystalline pellets of estradiol for conception control. Am J Obstet Gynecol, 1977; 127(5):520-524.

Breast Cancer
Glaser RL, York AE, Dimitrakakis C. Efficacy of subcutaneous testosterone on menopausal symptoms in breast cancer survivorsJ Clin Oncol 2014; 32 Suppl 2:109. 

Glaser R, Dimitrakakis C, Trimble N, Martin V.  Testosterone pellet implants and migraine headaches: a pilot studyMaturitas, 2012; 71(4):385-8.



Belmar Pharmacy  800.525.9473  I  303.763.5533  I  231 Violet Street, Suite 140  I  Golden, CO 80401